Most research on these drugs measures things. This one asked people what taking them was like, interviewing adults across 15 states (n = 30, of whom 23 were still taking a GLP-1 at the time and 7 had stopped) and sorting what they said into themes [1]. The quantified version of one of those themes is in food noise measured by memory.
The theme that matters most to anyone choosing where to buy is that clinical support and information were essential and highly variable. Patients were describing, from the inside, the thing this desk measures from the outside: that two sellers charging similar amounts can deliver entirely different amounts of care, and that what you are told to expect before starting varies enormously. The authors’ own conclusion is that standardized guidelines for patient education would improve expectation management.
A second theme is the one sellers are least likely to put on a landing page. Participants consistently described the drug as a facilitator rather than a replacement for lifestyle change — not a disclaimer they had been handed, but the conclusion they had reached themselves, and the reason the authors argue for behavioral support alongside the prescription.
One theme deserves reading in two directions at once. Participants reported being prepared to withstand substantial adverse effects and logistical difficulty in order to keep losing weight. That is a statement about motivation, and it is also a warning: a customer willing to tolerate a great deal is a customer who will tolerate poor service, slow shipping and thin clinical follow-up without leaving. The tolerance that keeps people on a drug also keeps them with a bad seller, which is part of why the discontinuation figures in two thirds stop within a year understate how much friction people absorb before they do.
Cost and access came up as prohibitive, and stigma came up as varying by what the drug was prescribed for — people treated for diabetes reported a different reception from people treated for weight. Both are the sort of thing that shapes whether someone stays on treatment and neither appears in any efficacy figure. What the market charges is in what a GLP-1 actually costs, and who is priced out of it in who the price filtered out.